KABS Laboratories Inc.
$36,657,400.00 CAD
- Program
- SIF Stream 2 - Growth
- Recipient country
- Canada
- Fiscal year
- 2020-2021
- Agreement period
- March 28, 2021 – July 2, 2050
- Reference
- ic:033-2020-2021-Q4-815813
Published purpose
The project aims to increase the company’s capacity for Good Manufacturing Practice (GMP) compliant bio-manufacturing in two separate factories of medium (new Val-des-Sources facility) and large capacity (existing St-Hubert plant) to produce biologics against COVID-19. The project’s work phase is scheduled to end on March 31, 2026.
In plain English AI-generated
Funding supports expansion of a biomanufacturing facility in St-Hubert, Quebec, and establishment of a new facility in Val-des-Sources, Quebec, to produce monoclonal antibody therapies and fill/pack them.
Category: Health Primarily funds activity in Canada
Based on the published description. See how AI categorization works — the linked official record is authoritative.
Community tags
Tags are applied by readers, not by this site. One tag per person per record.